Portal de Periódicos da CAPES

Naltrexone/bupropion for obesity: An investigational combination pharmacotherapy for weight loss

2014; Elsevier BV; Volume: 84; Linguagem: Inglês

10.1016/j.phrs.2014.04.004

1096-1186

Sonja K. Billes, Puspha Sinnayah, Michael A. Cowley,

Biochemical Analysis and Sensing Techniques

The mechanism of action of the combination therapy, naltrexone/bupropion (NB), for obesity has not been fully described to date. Weight loss attempts rarely result in long-term success. This is likely a result of complex interactions among multiple peripheral and CNS systems that defend against weight loss, and may explain the overwhelming lack of effective obesity treatments. NB is an investigational combination therapy for obesity that was developed based on evidence that obesity involves alterations in the hypothalamic melanocortin system as well as brain reward systems that influence food craving and mood. Naltrexone and bupropion both have actions in these brain regions that may cause them to influence food intake, food craving, and other aspects of eating behavior that affect body weight. We review the individual actions of naltrexone and bupropion in brain hypothalamic and reward systems, and describe the current in vitro, in vivo, and clinical evidence for how NB influences food intake and produces weight loss.